{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:33:00Z","timestamp":1779168780507,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004319","name":"Shin Kong Wu Ho Su Memorial Hospital","doi-asserted-by":"publisher","award":["2022SKHADR002"],"award-info":[{"award-number":["2022SKHADR002"]}],"id":[{"id":"10.13039\/501100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lungcan.2025.108751","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:19:19Z","timestamp":1757859559000},"page":"108751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score\u2013matched comparison"],"prefix":"10.1016","volume":"208","author":[{"given":"Wen-Pin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-6096","authenticated-orcid":false,"given":"Ju-Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5139-4659","authenticated-orcid":false,"given":"Shih-Sen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108751_b0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2022.10.009","article-title":"Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race\/ethnicity","volume":"174","author":"Pinheiro","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108751_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107826","article-title":"Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies","volume":"192","author":"Lundberg","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108751_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108751_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2007.07.012","volume":"59","author":"Rajeswaran","year":"2008","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108751_b0025","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cncr.22208","article-title":"Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase","volume":"107","author":"Ceppi","year":"2006","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2025.108751_b0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.9-suppl_2-16","article-title":"Taxane-platinum combinations in advanced non-small cell lung cancer: a review","volume":"9","author":"Rigas","year":"2004","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.lungcan.2025.108751_b0035","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108751_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10330-008-0148-2","article-title":"Effects of weekly docetaxel monotherapy schedule for elderly patients with non-small cell lung cancer","volume":"8","author":"Du","year":"2009","journal-title":"Chin. Ger. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108751_b0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.JTO.0000263713.38826.8e","article-title":"A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer","volume":"2","author":"Lilenbaum","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108751_b0050","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/sj.bjc.6602241","article-title":"A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study","volume":"91","author":"Gridelli","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108751_b0055","doi-asserted-by":"crossref","unstructured":"Rossi A, Gridelli C. Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol. 2006;17(Suppl 2):ii58-ii60. doi:10.1093\/annonc\/mdj925.","DOI":"10.1093\/annonc\/mdj925"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108751_b0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/etm.2012.597","article-title":"Comparison of docetaxel\/cisplatin dosages of 75\/60 and 60\/60 mg\/m2 for the treatment of non-small cell lung cancer","volume":"4","author":"Kim","year":"2012","journal-title":"Exp. Ther. Med."},{"issue":"9796","key":"10.1016\/j.lungcan.2025.108751_b0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108751_b0070","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cam4.2791","article-title":"Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: a retrospective study","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108751_b0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108751_b0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2019.01.005","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: a phase 1b and randomised, open-label, multicentre, phase 2 trial in Japan","volume":"129","author":"Watanabe","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108751_b0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108751_b0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108751_b0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","article-title":"Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer","volume":"17","author":"Cardenal","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.lungcan.2025.108751_b0100","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"Patel","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108751_b0105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","article-title":"Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer","volume":"76","author":"Niho","year":"2012","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108751_b0110","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108751_b0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.4-3-241","article-title":"Gemcitabine: single-agent and combination therapy in non-small cell lung cancer","volume":"4","author":"Sandler","year":"1999","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108751_b0120","first-page":"3819","article-title":"Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo","volume":"22","author":"Teng","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108751_b0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1759-7714.12472","article-title":"Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: a retrospective analysis","volume":"8","author":"Ma","year":"2017","journal-title":"Thorac Cancer."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108751_b0130","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-19-3060","article-title":"A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers","volume":"26","author":"Paik","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108751_b0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2019.01.007","article-title":"A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)","volume":"109","author":"Wang","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108751_b0140","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.10629","article-title":"The novel and effective non-platinum, non-taxane combination of gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: potential for decreased toxicity and combination with biological therapy","volume":"95","author":"Herbst","year":"2002","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108751_b0145","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108751_b0150","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108751_b0155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108751_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2000.18.2.405","article-title":"Phase I\/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer","volume":"18","author":"Lorusso","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108751_b0165","doi-asserted-by":"crossref","unstructured":"Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel versus carboplatin plus nab-paclitaxel as first-line therapy in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2018;36(18 Suppl):LBA9000.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108751_b0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108751_b0175","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1002\/onco.13527","article-title":"Expanding beyond maximum grade: chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729)","volume":"26","author":"Wong","year":"2021","journal-title":"Oncologist"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:55:47Z","timestamp":1772841347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"alternative-id":["S0169500225006439"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108751","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score\u2013matched comparison","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108751"}}